Presentation
7 March 2022 Fluorescent anti-CEA nanobody for rapid tumor-specific fluorescence labeling of patient-derived pancreatic cancer xenografts
Thinzar M. Lwin M.D., Michael A. Turner M.D., Nishino Hiroto M.D., Sophie Hernot, Michael Bouvet M.D.
Author Affiliations +
Abstract
Tumor-specific targeting with fluorescent probes can enhance contrast for identification cancer during surgical resection and visualize otherwise invisible tumor margins. Fluorescent probes derived from nanobodies, the smallest naturally occurring antigen binding molecules, can be used for in-vivo labeling with rapid pharmacokinetics. The present work demonstrates the efficacy of a fluorescent anti-CEA nanobody conjugated to an IR800 dye to target and label patient derived pancreatic cancer xenografts. After intravenous administration, the probe clearly localized to the pancreatic cancer tumors and had a tumor-to-background ratio of 2 or greater by 1 hour. Tumor-specific fluorescent nanobodies are clinically promising molecules for same-day labeling and imaging of tumors.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Thinzar M. Lwin M.D., Michael A. Turner M.D., Nishino Hiroto M.D., Sophie Hernot, and Michael Bouvet M.D. "Fluorescent anti-CEA nanobody for rapid tumor-specific fluorescence labeling of patient-derived pancreatic cancer xenografts", Proc. SPIE PC11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII, PC1194307 (7 March 2022); https://doi.org/10.1117/12.2609973
Advertisement
Advertisement
KEYWORDS
Tumors

Luminescence

Pancreatic cancer

Molecules

Surgery

Cancer

Field emission displays

Back to Top